AMISTAD II

AMISTAD II

Acute Myocardial Infarction Study of Adenosine II. A trial evaluating adenosine as an adjunct to thrombolytic reperfusion in decreasing the size of MIs
s,  
Primary endpoint
Mortality, new heart failure.
 
Conclusion
Somewhat helpful at higher doses but not statistically significant.
References in periodicals archive ?
Food and Drug Administration in September in order to review the design of AMISTAD II.